Earnings call transcript: Covalon Technologies Q3 2025 reports revenue miss

Covalon Technologies Ltd. reported its Q3 2025 earnings, revealing a revenue of $8.4 million, which fell short of the forecasted $10.38 million. Despite the revenue miss, the stock price increased by 3.23% to $2.88, indicating investor optimism driven by strong cash reserves and product innovations. According to InvestingPro data, the company maintains a market capitalization of $28.91 million and demonstrates strong financial stability with a current ratio of 16.7, indicating robust liquidity management.

Key Takeaways

• Revenue for Q3 2025 was $8.4 million, missing the forecast.
• Stock price rose 3.23% to $2.88 post-earnings.
• Strong cash position with $18 million, up from last year.
• New product innovations and high customer retention.

Company Performance

Covalon Technologies demonstrated a 10% sequential revenue growth from Q2 2025, although it failed to meet the market’s expectations. The company continues to benefit from its strategic focus on the healthcare market, particularly in the advanced wound care and vascular access segments, which represent the bulk of its revenue.

Financial Highlights

• Revenue: $8.4 million in Q3, 10% growth from Q2.
• Adjusted EBITDA: Nearly $1 million, a 50% sequential increase.
• Cash position: Over $18 million, a significant improvement from last year.

Earnings vs. Forecast

Covalon’s Q3 revenue of $8.4 million did not meet the forecast of $10.38 million, reflecting a significant miss. The absence of explicit EPS data in the earnings call summary prevents a direct comparison to the forecasted $0.07 EPS.

Market Reaction

Despite the revenue miss, Covalon’s stock price increased by 3.23% to $2.88. This movement suggests investor confidence, possibly due to the company’s strong cash position and innovative product launches. InvestingPro analysis indicates the stock is currently trading above its Fair Value, with a relatively low beta of 0.78, suggesting lower volatility compared to the market. The stock trades at -15.89 times earnings and remains closer to its 52-week low of $0.20, indicating potential for further recovery. For deeper insights into Covalon’s valuation and growth potential, investors can access comprehensive Pro Research Reports available on InvestingPro, covering over 1,400 US equities.

Outlook & Guidance

Covalon Technologies is optimistic about sequential growth in Q4 2025 and anticipates strong momentum heading into 2026. The company is exploring capital allocation options, including machinery investments, potential acquisitions, and shareholder returns through dividends or buybacks. InvestingPro highlights that the company holds more cash than debt on its balance sheet, with sufficient cash flows to cover interest payments. InvestingPro subscribers can access 8 additional key insights about Covalon’s financial health and growth prospects.

Executive Commentary

CEO Brent Ashton emphasized the company’s strategic focus, stating, "We’re investing in driving actions that are creating strong shareholder value creation." He also highlighted the benefits of Covalon’s North American manufacturing strategy, which remains tariff-free.

Risks and Challenges

• Revenue miss may affect future investor confidence.
• Inventory charges impacted gross margins.
• Potential challenges in maintaining growth amidst economic uncertainties.

Q&A

During the earnings call, analysts inquired about the strategic advisory engagement and market potential for new product applications. The management confirmed a positive competitive environment and manageable inventory levels.

Full transcript - Covalon Technologies Ltd. (COV) Q3 2025:

Joelle, Conference Operator: Good morning, ladies and gentlemen, and welcome to the Covalon’s Q3 Fiscal twenty twenty five Conference Call and Webcast. My name is Joelle, and I will be your conference operator today. As a reminder, today’s conference is being recorded. All lines have been placed on mute to prevent any background noise. After the speakers’ remarks, there will be a question and answer session.

If you would like to ask a question during this time, you could submit your typed questions via the webcast. At this time, I would like to turn the conference over to Mr. Brent Ashton, Chief Executive Officer.

Brent Ashton, Chief Executive Officer, Covalon: Hey. Thank you so much, Joel, and good morning to all of you on the call today. We really appreciate you connecting in. I’m joined today by Kim Crooks, our chief operating officer, and Katie Martinovich, our interim chief financial officer. And Salya Asazara from Covalon is also helping to coordinate the conference call and the webcast today.

Salya will now provide us with some instructions.

Salya Asadzara, Executive Assistant to CEO, Covalon: Thank you, Brent. Good morning, everyone. My name is Salya Asadzara, and I am the executive assistant to Covalon’s chief executive officer. I would like to thank everyone for joining for taking the time this morning to attend our conference discussion, I would like to remind participants that this call and webcast are covered by Covalon’s safe harbor statement. Please read the safe harbor statement on this slide.

This is also available on our website. I will now turn the call back over to Brent Ashton, Covalon’s chief executive officer.

Brent Ashton, Chief Executive Officer, Covalon: Hey. Thanks, Saleh. And it’s great to be able to speak with all of you. So thanks for taking the time to engage with us today. I’m really excited to be with you today and share the strong progress that Covalon is making.

During today’s call, I’ll be discussing the following topics. First, I’m gonna start with some really amazing thoughts by Jaden. She’s a patient that our team and I had the opportunity to hear from a few weeks ago, and she’ll share some comments about the life changing impact of Covalon technology. Second, I’ll share some really encouraging recent highlights from Covalon that will have a strong impact on our short and long term future. Third, I’ll dive into our financials.

During last quarter’s earnings call, we shared that we had solid line of sight to sequential quarter on quarter revenue growth for Q3, and I’m happy to report that we’ve delivered on this. We will show some key sequential quarter on quarter metrics, and then we will also review our Q3, our year to date and the trailing twelve months financials. And as we’ve done for the past four quarters, we’ll also showcase some key metrics from our U. S. Vascular Access and Surgical Consumables business segment.

Fourth, we’ll dive a little deeper into our innovation and business development work that we have been driving over the past few quarters. This work is an important part of our plans to transform Covalon and make an even bigger difference in the lives of patients and the clinicians who serve them. And then we’ll wrap up and take questions. We will prioritize questions via the web interface. So as we are going along here, please feel free to type your questions in.

So last quarter, I had the privilege to share the story of Sandy, a nurse leader at one of the top children’s hospitals in The US, and how she uses Covalon technology to help protect her patients. This quarter, I’d like to highlight a different perspective from the patient side, the story of Jaden. Jaden is a young woman living with multiple complex conditions, including Ehlers Danlos syndrome, which is a connective tissue disorder, intestinal failure, which requires her to receive nutrition through a central venous catheter, and postural orthostatic tachycardia syndrome, a cardiac condition which requires IV fluids. For Jaden, a central line isn’t just part of her care plan. It is literally her lifeline.

And when we first met Jaden, she described the struggles that she faced with traditional IV dressings. Every dressing, even those labeled for sensitive skin, would leave her skin red, itchy, and painful. Dressing changes left her feeling completely defeated, and clinicians told her this was just simply something she would have to live with. That completely changed when she began using Covalon’s IV Clear, our dual antimicrobial silicone adhesive based gentle to skin IV securement dressing. In her words, the difference has been life changing.

Her skin is healed. It’s no longer red or itchy or painful, and dressing changes are no longer something she dreads. She also talks about how she can clearly see the IV site without other devices covering it, which allows her to gauge early potential signs of infection. Covalon’s amazing technology give pay gives patients like Jaden relief from the trauma and pain that they had come to expect. Like Sandy last quarter, Jaden represents the very real impact our solutions have on clinical outcomes, but also on the dignity and quality of life for patients.

These stories remind us why we come to work every day at Covalon, to advance care, to protect patients and to do so in a way that blends strong clinical performance with compassion. So with Jaden’s story as a small view into a bit of our why as a company, I’ll now move into some really exciting recent highlights since we last spoke back in May. Last quarter, we provided some insights into early returns from Covalon’s focus on market development and clinical evidence generation and dissemination. Momentum continues to build here and the next few weeks are just going to be such an amazing time as we share some of these advancements with our customers. You might recall from last quarter about a very impactful study that was conducted on our ValGuard vascular access line guard, is our fastest growing product.

To recap, this was a study by a team of nurse researchers at a large well known children’s hospital in The United States. The study was focused on reducing central line associated bloodstream infections, better known as CLABSIs. In The United States, these CLABSIs carry significant financial penalties that are in place to incentivize hospitals and other providers to take steps to continue to reduce these infections. Accordingly, infection prevention is a big priority for hospitals, and they’re investing large sums of money to help reduce these infections. This hospital had already implemented a number of prevention steps but wanted to take additional actions to lower their infection rate, and so they decided to begin using Covalon’s Vowgard product.

This one change in their infection prevention protocol was able to drive a very significant reduction in their bloodstream infection rates in the departments that use Vowel Guard in the trial. So to update on progress here. First is that we can now share that the study has successfully passed through the peer review process, which is very rigorous and will publish in mid September in the fall edition of the Journal of the Association for Vascular Access, a very well regarded scientific publication that is trusted by thousands of vascular access clinicians in The United States and around the world. Given the confirmed publication, we’re also in a position to publicly share the name of the hospital that did this work. It is the Children’s Hospital at Montefiore.

Located in New York City, CHAM, as it is most commonly referred to, is a premier academic children’s hospital, nationally renowned for its clinical excellence, innovative research, and commitment to training the next generation of pediatricians and pediatric subspecialists. Each year, CHAM cares for over nine thousand hospitalized infants, children, and adolescents with complex medical and surgical conditions, including eleven hundred in their state of the art pediatric critical care unit and approximately nine hundred critically ill newborns in their neonatal intensive care units. The CHAM team have been absolutely fantastic to work with on this initiative, and we are very grateful for the partnership here. The work they do at CHAM is nothing short of amazing. You might also recall me sharing that this study was selected as a poster at September’s Association for Vascular Access, their annual scientific meeting, which is the premier platform for the latest innovations and emerging technologies in vascular access.

A few weeks ago, we were delighted to learn that this topic has been elevated to be one of only four topics to be presented from the podium in a breakout session focused on pediatric vascular access topics, which will give even greater visibility to this impactful and rapidly growing technology from Covalon. We are also still on track for this study to be presented as a poster at October’s ANCC Magnet Pathway Conference, which attracts more than 11,000 nursing leaders and professionals from around the world. We expect this type of clinical evidence dissemination to be a significant growth accelerator for the adoption of Covalon’s amazing technology. A few other notable highlights. Covalon has advanced the new use case for our Covalon silicone dressing that is really starting to generate significant interest.

Due to some strong testing work by our team, we’ve been able to add a new indication for this product. This new use case indication offers customers strong clinical and economic benefit, and we see this as an exciting new revenue opportunity. We’ll cover this in more depth in a few slides when we dive a little deeper on innovation. And switching gears to the investor side, we’re very pleased to be able to share that our common shares are now eligible for electronic clearing and settlement in The United States through the Depository Trust Company. This is commonly known as being DTC eligible.

This eligibility process has successfully been completed and will make it much easier for retail shareholders in The United States to be able to invest in Covalon. This has been a bit of a gating factory in gating factor in the past for a large number of US based investors, and so we’re excited to be able to make it easier for them to invest in Covalon and share in our journey here. And on the international front, happy to report meaningful progress on several areas. We’ve successfully registered our fast growing VialGuard line LingGuard product in Canada, Brazil and Panama and have seen strong initial interest there, which will only accelerate in the coming weeks with the clinical evidence we discussed earlier. We signed a new distribution agreement with a new partner for Israel, Labi Partners, and are excited for growth prospects there.

And last but not least, Covalon was recently awarded a new tender for our IV Clear product in India. Our international business has had a strong year of growth so far, up more than 35% year to date, and we see these advancements paving the way for a robust future. Moving to the financial side, given our commitment last quarter to achieve sequential quarter on quarter growth here in Q3, we thought it would make sense to share this view in a little more detail. Revenue at $8,400,000 was up more than 10% sequentially between Q3 and Q2, led by more than 40% sequential quarterly growth in our U. S.

Advanced Wound Care sales channel. Our gross profit and gross margin were down compared to last quarter, but this was a function of more than $800,000 of charges related to the destruction or provisioning for obsolete or slow moving inventory or product that didn’t meet our high quality standards. The vast majority of this amount was the final cleanup from our CovaWound and CovaView excess inventory build that dates back several years ago. Excluding these largely one time costs, our adjusted gross margin was more than 55% for the quarter, representing an improvement over last quarter’s adjusted gross margin. Adjusted EBITDA performance was strong on a sequential quarter on quarter basis, more than 50% higher than last quarter at almost $1,000,000 And then zooming out to various time horizons, you can see Covalon’s quarterly, year to date and trailing twelve months performance.

Looking at just Q3, we came in at $8,400,000 of revenue, which came in 9% below last year’s Q3, which was our highest revenue quarter of 2024. And adjusted EBITDA was just under $1,000,000 which was a $1,500,000 decrease from Q3 of last year. On a year to date basis, with us being three quarters of the way through the year, we’ve got 8% growth on revenue and $3,000,000 of adjusted EBITDA, which is down slightly from last year to date. And then from a trailing twelve month standpoint, solid revenue growth at 13% and adjusted EBITDA more than double the prior period. Across all three of these time lenses, we’ve continued to demonstrate smart spending and investment in operating expenses, which have come in the high 40s as a percent to our revenue.

On the right hand side of the slide, you can see a good view of our FY 2025 year to date revenue performance compared to the same Q1 to Q3 look from the prior three years. This lens is looking at our worldwide product revenue, both the Advanced Wound Care, which is primarily our collagen business, as well as our Vascular Access and Surgical business segment. It’s a worldwide view, so it includes both U. S. And international.

For 2025 to date, these business segments represent over 99% of our revenue, so it’s a very good view to the current laser focus of the company and how these business segments have performed over the past few years. With this focus, we’ve clearly been winning in the marketplace, more than doubling our revenues in the past three years and achieving a three year compounded annual growth rate of 27%, which is around five times the underlying market growth rate of the spaces that we play in. And from a cash generation standpoint, we sit today at just over $18,000,000, up almost $9,000,000 from a year ago, and we’ve grown our cash on hand each of the past five quarters. This cash position is rare for a company of our size and gives us tremendous optionality. In addition to the slides here, you can go to the presentation on our website and in the appendix, we have additional financial details on Q3, Q3 year to date and our trailing twelve months as well as each of our past eight quarters.

Looking at The U. S. Vascular Access and Surgical Consumables sales channel a little more closely, we continue to be a strong partner to the top children’s hospitals in The U. S, demonstrated by eight out of the top 10 of those best hospitals counting on Covalon to help them deliver superior outcomes for their patients. And then looking at the metrics that we believe are important KPIs for this sales channel, as we look at our top 50 U.

S. Hospital customers from last year, in terms of retention of these important customers that we’ve worked hard to acquire and grow, we’ve maintained 100% success in retaining all of these 50 customers. This reflects the stickiness and the value of our products, and it also reinforces the strength of Covalon’s post implementation engagement model, including clinician support, education and continuous value delivery, which ensures sustained adoption well beyond initial conversion. Our second priority is to grow our existing accounts, either by adding new products that they weren’t previously purchasing or by growing volume of existing products in the account. Here, we’ve seen solid revenue growth of 25% year to date from the same group of our top 50 hospitals from last year.

And third is around adding new customers. In q three, we added 15 new hospital accounts to our revenue roster, which takes us to 65 new hospitals through the first nine months of the year, which is basically even with our total of 66 from all four quarters last year. Importantly, we are not simply focused on acquisition volume and chasing a number. We’re also investing in deepening engagement and product use across these new hospitals from the outset, which supports long term revenue growth and retention. And then transitioning to the next part that I told you I’d walk through today.

Three quarters ago, I showed this slide and talked at a high level around the importance of these four areas of advancement for Covalon and their importance to our multiyear growth journey. I’ve previously covered commercial advancement and market development areas. And today, I’d like to go a little deeper around the innovation and business development side of things. Next quarter, we’ll close this out by covering our operational optimization. While Covalon has done a remarkable job of growing with the current products we have and with our existing strategic partners, we see innovation and business development as a critical piece of how we will transform Covalon and make a massively larger impact to patients, the clinicians who serve them, and our customers and partners.

On the innovation side of things, over the past year, we’ve made solid progress in shifting our innovation prioritization from being largely sustaining focused to being, largely growth focused. In doing so, we’ve more than tripled the size of our innovation pipeline, building strength across three key states, advancing fully resourced prioritized programs towards defined timelines and outcomes, investing in early stage work opportunities that we believe have strong promise and drawing upon a significant shift externally for Covalon to generate new ideas and concepts that can shape the future. We’ve also increased our emphasis in three critical areas. First, in addition to existing work around line extensions or new shapes and sizes, we’re more actively focusing on new products, both those that are new to Covalon and those that are brand new to the world. Second, we’re expanding our intellectual property focus, including work on picket fence strategies to strengthen our competitive mode on key products.

And third, we’re pursuing new use cases, indications, and claims that will help us unlock even more value from our existing technologies. For those of you who aren’t as familiar with these kinda med tech centric terms, on the next slide, I’ll double click to an example. And then on the business development front, a lot of encouraging work here where over the past year, we’ve had dozens of discussions with other companies to look at potential partnerships or other inorganic opportunities. It’s been exciting to be able to examine the art of what might be possible with this exciting external engagement. So while new products are what most people think in terms of innovation, I’m also a huge fan of innovation applied to existing products, specifically new use cases, new indications, and new claims.

And on this slide, you’ll see a really exciting new use case and indication for Covalon’s CovaClear IV product line. This product has been on the market for several years now, but this new use case is relatively new and we’re starting to see a rapid increase in interest. So from a foundation, the initial reason why Covalon launched Covalon IV was as a primary IV securement dressing for an IV catheter. You can see a picture of this use on the left hand side of the slide here where CovaClear IV is being used to secure and protect a peripheral IV. And so when you have a single IV dressing in place, and this could be our CovaClear IV like you see on the left, but most commonly in the market is a three ms taggiterm, a Medline Sorbivu, or a Smith and Nephew IV 3,000.

When you have a single primary dressing and that dressing becomes soiled, and and I hope none of you are eating your breakfast listening to this, but when the dressing becomes soiled, this could be where the patient is vomiting or has a kind of liquid ish bowel movement where some of it ends up on top of the dressing or if they were to spill food or drink onto the dressing surface. No matter the cause, if the the dressing becomes soiled, there’s a standard protocol that calls for an entire dressing change. Now this just isn’t change the dressing and put it back on. It involves a whole set of steps, including prepping the skin with an alcohol or CHG containing skin prep, maneuvering the IV catheter, and a whole bunch of other steps. And the whole process typically takes two nurses about fifteen or twenty minutes to do, and it can involve as many as 10 different products that can include a new dressing, adhesive remover, skin prep, gloves, a mask, a securement device, and so on and so on.

And in doing this procedure, you also increase the risk of complications such as catheter dislodgement or bloodstream infections. So the new use case that we are talking about here, nurses are colloquially referring to it as a mud flap application. And when you think about what a mud flap does on a truck, right, it keeps dirt and mud from getting all over the back of the truck. Well, this new mud flap use case uses our CovaClear IV to keep things like vomit and liquidy bowel movements and spilled drinks and whatnot from coming into contact with the primary IV securement dressing, which would then require this dressing change. So think of this use as a cover dressing or protective dressing that keeps the primary dressing intact and nonsoiled.

If the CovaClear IV mud flap application does get soiled, you just peel it off, put a new one on, which preserves the integrity of the primary dressing underneath. This just takes seconds to do and it’s just one product, a new CovaClear IV dressing. And so for the clinician and for our customers, this saves a ton of time and money spent on supplies and can also help protect against the complications I mentioned earlier, such as catheter dislodgement or bloodstream infections. On the economic side, we’ll be sharing some more details in a couple of weeks, but some early insights we have from a poster that a large influential US children’s hospital will be presenting at the Association for Vascular Access meeting in a few weeks suggests that using this CovaClear mudflap application has delivered about $2 in savings for every $1 spent on the CovaClear IV. So a really strong economic benefit in addition to the compelling clinical benefits.

We see this as a sizable opportunity in both children’s hospitals as well as on the adult side. And we also see it as a really great way to get into an account to kind of break into an account that we’re not in today, where once we’ve established our our presence, our team can then advance various cross sell opportunities to get the broader Covalon portfolio to be used by the hospital. So a very exciting new use case. So to wrap up today’s call so that we can then take questions, a quick summary. The impact that Covalon’s amazing technology is having with patients, the clinicians who serve them, and the health care providers is significant.

You heard that in Jaden’s words, and our team sees this every time we’re blessed with the opportunity to work with our customers to help them solve their challenges. We’re advancing a lot of work to demonstrate how Covalon’s products improve our customers’ clinical and economic outcomes. We’re investing in driving actions that are creating strong shareholder value creation, and there’s a very exciting future ahead for Covalon. We couldn’t be more motivated and and driving for that multiyear growth journey. And with that, we’ll transition to our q and a.

We’ll take a short pause here for a few seconds and then start with questions that are typed into the q and a feature here online. So we’ll take about a thirty second pause here to get things in order and then answer your questions. Okay. I think I think we’re ready to start. We’ve got a a number of questions here.

The first question, there’s there’s actually a couple questions on this front, and it was essentially around Covalon hiring Origin Merchant Partners as a financial and strategic adviser. Has there been any progress in the last three months? And and, yes, there’s been a ton of progress, a lot of, really exciting engagement. It’s one of those processes that once we have something to announce, we will. But I would say, it’s been it’s been very, a very encouraging process to date.

And when, when there’s, an outcome that, warrants, advising on, we will do that. There was a second part of this question, from the first person who asked it around last quarter, Covalon had clear line of sight via in house orders forecast and recent strategic partner sellout trends to a strong q three. Do you have line of sight into the current quarter now almost two thirds complete? And there was a similar question from Matthew Martin around strong last quarter, we had strong visibility into or we had visibility into a strong second half of the year. Can we comment on the outlook for the rest of the fiscal year and going into next year?

And so, yes, you know, we we were, you know, a little over halfway through the quarter, and we continue to stand by that strong second half. We think we’ll see we’re expecting to see sequential quarter on quarter growth in Q4 over Q3 as well from a revenue perspective. And so, yeah, bullish, about our continued sequential growth here and, strong, strong growth heading into next year as well. Arnold Shell has a question about are you are you really as happy as you seem to be? And and I guess, you know, for sure, I guess if the, you know, the, when we think about the the business, I’m I’m really bullish.

I’ve given you a lot of examples of the solid progress that we’ve made and the difference that we make saving lives, nurses and doctors raving about our products. You know, I’m really proud of the financial turnaround that we’ve made from a few years ago. And another thing that I think people tend to overlook, you know, health care is not a fad. It’s not going away. It’s grown every year.

You know, the the broader health care space has grown every year for forever. It’s the only industry that has not had any real downturns. And and, you know, so when we think about investors, yes, you know, some some could probably make a little little more money if they time the right hot sector of the day, but the macro is solid. And I I’m I’m and the team are really proud of the accomplishments we’ve made. We hit on some of the things, like, on the market development side, the international front that we believe, will be a really, really exciting, future for us.

So hope, that, that answers that one. There’s a question around, you know, material drop in trailing twelve months adjusted EBITDA. And as I’m reading this, and, you know, do we expect improvement? And the answer is yes. Absolutely.

We as we head into q four here, as I said, we’re we’re bullish on a stronger finish to the year. We we see margins stabilizing from the kind of onetime events we had here in q three. And as we look at 2026 and beyond, the actions that we’re taking were committed to, and and believe it’ll be a strong growth picture for the company, which will drop to, you know, we’ve demonstrated very strong, management on the spending line. So as as those that revenue growth and margin, stable margins drives clear EBITDA, we do expect, that to, to be strong for us. Yeah.

There’s a question from Andrew Rem around, like, the the total addressable market or the the addressable market for the mud mud flap use case. You know, just just looking at that there’s we think it’s huge. Tens of millions of dollars from a total addressable market standpoint. We’re not gonna get there overnight, but, we do think we’re gonna get off to a fast start here as we roll this out. But when you think about just the the sheer number of patients that, have these kinda contamination events, whether that’s in a a PICU or or NICU or any pediatric part of a hospital or elder patients.

It’s kind of, I guess, usually the the bookends of the lifespan there where these things tend to be the most prevalent. We’re talking about tens of thousands of patients every year, hundreds of thousands of patients. And and as I explained, right, there’s so there’s clinical benefit for this. But one of the things I really love about this this application is through the study that we’ll be sharing more details on when it, is presented in a couple weeks, there’s a strong economic benefit as well. And so for hospitals that are, you know, in the in The US in particular and really all around the world that are looking for cost savings and whatnot.

This is a clear winner. So, you know, tens of millions of dollars in terms of a a broad based total addressable market. For Covalon, we think this can can be a strong multimillion dollar use case for us in the coming years. There’s a question here from Jurian Hoffman around elaborating on inventories at your customers and distributors and our thoughts on the current levels of inventory in the system and underlying sellout trends. And so on on that side of things, yeah, when we look at so, really, two different businesses in The US.

One is around our US vascular access and surgical consumables business. And for that, the vast majority of our revenue actually is done directly with the hospitals. We do have a a smaller portion that goes through distribution where they might keep, thirty days of inventory on hand is pretty typical. The hospitals themselves tend to keep a little bit less. So I’d say, you know, that that’s a very manageable part of our inventory position.

With with The US advanced wound care business, there, those strategic partners keep a little more of inventory on hand. And, you know, we do have visibility in some cases to the sellout. We’re really encouraged by the sellout trends there, and and we we think it sets us up really well heading into 2026 here. Jurrien also had a question around, have you noticed any changes in the competitive environment? Has there been any been any impact from The US trade tariffs on that?

And it’s a great question, so thanks, Yurian. I would I would answer that. We are seeing some changes. And and the tariff in particular, we’re we are seeing an uptick in interest and and orders around our Advanced Wound Care platform in The US where a sizable sizable percentage of the the other competitors there manufacture either in China or The UK or Germany. And and China in particular, those tariffs are a lot higher.

I think they’re currently you know, I I probably best to to look at CNBC right now because they do seem to change every every pretty frequently. But I think at last gas, they were around 30% with a threat of perhaps doubling to 60%, but there’s a pause. But we are seeing that that play out, and so I think it’s a very good benefit for us. The UK and Germany are are lower. I think they’re 1020% respectively, but so we’re seeing we’re seeing that as well.

And then just broader, we are we are seeing a broader trend, and not just us, but as I talk to other companies, you know, relative to medical products made in China. And and so we’re we are seeing that have an impact where I think we’re seeing more US and other countries shift away from made in China to for a variety of reasons, tariffs are one, to, you know, products made more in kind of The Americas or or parts of Europe and The Middle East. Specific Arnold had another question more specific to the tariff situation. So, yeah, just to expand upon that, you know, we we still maintain a competitive advantage here. 99% of our revenue into The US goes out tariff free, and the vast majority like I said, the vast majority of our competitors in the wound care space are seeing these tariffs.

So, you know, I I’m not gonna opine on where where the The US trade policy will go in the future, but I would say in the in the current state, we, at Covalon, definitely view it as a competitive advantage for our company and our North American centric manufacturing strategy is is paying good dividends. And I think I think that’s it on the questions. Just let me look back here. Oh, sorry. Mark we had kinda two questions from Jurrien that we lumped together.

Mark Has has a question on capital allocation strategy. Do we have any CapEx needs, m and a, and CIB? And so, you know, on on on that front, we are amazingly fortunate to have a lot of really great options on the table or in development. Should we invest in machinery and automation to lower our costs? Yes.

Absolutely. Good idea, and we’re doing that. We’ve got two two investments in the hundreds of thousands of dollar range that are going to drive strong costs out. Should we spend money on acquisitions? Yes.

Those can absolutely be transformative. We’re working on this. Should we do dividends or share buybacks? Yeah. There’s there’s pros and cons to those, and those are discussions we have at the board level.

But overall, it’s just so great to have the options. There are a lot of smaller cap companies out there that are struggling to see how they’ll keep their payroll going next month, And I’m really glad that that that is aware myself or our team have to spend our time. We we’re able to spend it much more on the growth and future side of things. And so with over $18,000,000 in the bank, as I said, that’s a a a large sum of cash and great optionality to have for a company of our size. So that’s it from the queued questions.

At this point, it sounds we’re hearing from the operator that there are no questions from phone people people on the phone. And so with that, you know, if you stayed on the call until now, you’re clearly very interested in Covalon, and we appreciate that a ton. I’d like to close with an ask here. If you don’t already follow Covalon or myself on LinkedIn or on our company’s various social media platforms on X or Instagram or Facebook, I would encourage you to do so, and you can see those at the bottom of our press release. You won’t have to wait until next quarter to hear and see some highlights.

We’ll be providing some great updates from these two major scientific meetings that will be at in September and October, and it’ll give you a feel for the the the excitement that was just building and that we’re really bullish on, and that we’re generating that with our current and future customers. You’ll So definitely be glad that you did. Beyond that, I just hope that each of you have a great rest of your day and a great rest of your summer. All the best, and thank you so much for your strong support of Covalon. Have a great day.

Joelle, Conference Operator: Ladies and gentlemen, this concludes your conference call for today. We thank you for participating and ask that you please disconnect.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.